230 results about "Macrocycle Compounds" patented technology

Related to macrocyclic compounds and therapeutic uses thereof. Disclosed a compound of formula (I), or a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt, and their use for the preparation of a medicament of treatment of cancer. Provided herein are useful compounds for the inhibition of RAS mutant and the compound shows good inhibitory activity against RAS.

The present invention provides macrocyclic compounds, the use thereof for selectively inhibiting the activity of RAS mutants, and pharmaceutical compositions comprising the compounds, e.g., for treatment of various diseases including cancer.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The disclosure provides solid forms of Compound A, as described herein. The disclosure also provides pharmaceutical compositions comprising the disclosed solid forms and methods of using the disclosed solid forms and pharmaceutical compositions (e.g., to treat cancer).

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder

The invention discloses a composite separation membrane for enriching < 6 > Li isotope and application. The composite separation membrane comprises a functional membrane and at least one supporting membrane; the functional film comprises a plurality of pore channels penetrating through the first surface and the second surface of the functional film, and the pore channel diameter of each pore channel is 0.4-0.7 nm; a lithium ion trapping functional group or a macrocyclic compound and a derivative thereof are modified at an inlet of the first surface of the pore channel. The strength of the lithium isotope separation effect depends on the diameter of a pore channel of the composite separation membrane and functional groups modified at an inlet, does not change along with the migration time and the lithium ion migration proportion, and has long-term continuous stability.

Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The present invention relates to a macrocyclic compound and a therapeutic use thereof. Disclosed in the present invention is a compound of formula (I), a pharmaceutically acceptable salt of said compound, a solvate of said compound, or a solvate of said pharmaceutically acceptable salt, and a use thereof in the preparation of a drug for treating cancer.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The invention provides a novel macrocyclic compound, a gadolinium chelate thereof, a method for preparing the compound and application of the compound as a magnetic resonance contrast agent. The compound has pertinence on magnetic resonance detection of liver focal lesions and can be used for liver specific imaging.

The present invention relates to macrocyclic compounds and therapeutic uses thereof. Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, solvates thereof or solvates of the pharmaceutically acceptable salts, and their use in the preparation of medicaments for the treatment of cancer.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The present disclosure provides compounds of formula (I), pharmaceutical compositions thereof, and uses thereof in the treatment and / or prevention of diseases or conditions associated with CDK9 kinase activity. JPEG2025538275000286.jpg3450

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The present invention relates to a nitrogen-containing macrocycle derivative regulator, a preparation method therefor, and a use thereof. In particular, the present invention relates to a compound represented by general formula (A), a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof as a regulator in the preparation of a drug for treating metabolic diseases and related diseases, each substituent in general formula (A) being as defined in the description.

The invention relates to a macrocyclic compound, a pharmaceutical composition and application of the macrocyclic compound. The macrocyclic compound has a structural formula as shown in a formula I. The macrocyclic compound is a TYK2 allosteric inhibitor with high blood brain barrier passing ability and high selectivity, and can be used for regulating TYK2 mediated diseases.

To provide a method for producing a bipyridine derivative, which enables obtaining a high-purity target compound (including an intermediate) without performing purification by column chromatography, provides a high yield, and is industrially advantageous.SOLUTION: A method for producing a bipyridine derivative represented by formula (3) comprises a step of obtaining a metal complex as an intermediate. In the formula, each of R13 to R20 is a hydrogen atom or a substituent; a plurality of R13 to R20 may be the same or different; at least one of six R14 to R16 is a substituent; at least one of two R17 is a hydrogen atom; any two substituents of R13 to R20 may be linked to each other to form a ring; R17 to R20 may contain a pyrrolyl group which may contain a halogen atom or a substituent; and at least one of R14 to R16 may have a halogen atom or a substituent.SELECTED DRAWING: None

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

The present disclosure relates to a macrocyclic compound represented by formula I, a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt, prodrug, solvate, polymorph, isomer and stable isotopic derivative thereof, a preparation method therefor, and a use thereof as a TRK, ROS1, c-Met, CSF1 and / or ALK inhibitor.